When the dust settles… (after COVID-19)
By James W. Kim
As the world continues to grapple with COVID-19, it’s worth looking ahead to what the post-pandemic healthcare landscape might look like. Not the immediate aftermath — the vaccination campaigns, the economic recovery packages, the reopening debates — but the structural changes that will persist long after the virus is contained.
What Will Change Permanently
1. Diagnostic testing will never go back to pre-pandemic levels.
Before COVID-19, the idea of mass population screening for an infectious disease was considered logistically impractical and economically unjustifiable in most settings. The pandemic proved otherwise. We built testing infrastructure — from PCR labs to rapid antigen test supply chains — at unprecedented speed and scale.
This infrastructure will not be dismantled. Instead, it will be repurposed. The rapid test manufacturing capacity alone represents a transformative asset for infectious disease management. Expect to see widespread point-of-care testing for influenza, RSV, strep, and other common infections become the norm rather than the exception.
2. mRNA technology will transform the pharmaceutical landscape.
The speed at which mRNA vaccines were developed and deployed was nothing short of revolutionary. What took years with traditional approaches took months with mRNA platforms. This technology will be applied far beyond COVID-19 — to influenza, RSV, cancer immunotherapy, rare genetic diseases, and more.
The investment in mRNA manufacturing capacity during the pandemic has created a platform that will yield returns for decades. Companies like Moderna and BioNTech are already pivoting their COVID-19 infrastructure toward these new applications.
3. Supply chain sovereignty will become a healthcare security issue.
The pandemic exposed the fragility of global pharmaceutical and medical device supply chains. When borders closed and export restrictions were imposed, countries that depended on imported healthcare products found themselves vulnerable. This lesson will not be forgotten.
Expect to see increased government investment in domestic pharmaceutical and diagnostic manufacturing capacity, particularly in countries that found themselves dependent on Chinese and Indian API (active pharmaceutical ingredient) supply chains.
4. Digital health and telemedicine will plateau at a new, higher baseline.
The pandemic forced rapid adoption of telemedicine and digital health tools. While some of this adoption will revert as in-person care resumes, the baseline has permanently shifted upward. Patients who discovered the convenience of virtual consultations won’t entirely give them up, and health systems that invested in digital infrastructure will continue to use it.
What Won’t Change
1. Healthcare inequality will persist.
If anything, the pandemic has widened the gap between healthcare haves and have-nots. Wealthy countries vaccinated their populations while poor countries waited. Within countries, marginalized communities suffered disproportionate mortality. These structural inequalities predate the pandemic and will outlast it.
2. Pharmaceutical pricing debates will continue.
The pandemic added fuel to both sides of the pricing debate. Advocates for lower prices pointed to government funding of vaccine development as justification for price controls. Industry advocates pointed to the same rapid development as evidence that the incentive structure works. Neither side moved.
3. Regulatory frameworks will remain slow to adapt.
Despite the impressive speed of COVID-19 vaccine authorization, the underlying regulatory frameworks haven’t fundamentally changed. Emergency use authorizations were possible because they were already provided for in existing regulations. The bureaucratic structures that make routine drug approval a decade-long process remain intact.
The Opportunities
For healthcare companies — and for countries — the post-pandemic landscape presents several opportunities:
Diagnostics companies should be investing heavily in next-generation platforms that can leverage the testing infrastructure and consumer behavior changes created by the pandemic. The market for rapid, decentralized testing has been proven at scale.
Pharmaceutical companies should be building mRNA and other platform technology capabilities. The pandemic demonstrated that the ability to rapidly develop and manufacture products is a strategic asset, not just an R&D capability.
LMICs should be using this moment to invest in domestic healthcare manufacturing. The case for supply chain sovereignty has never been stronger, and international funding for such initiatives has never been more available.
Governments should be establishing permanent pandemic preparedness infrastructure — not just stockpiles, but standing manufacturing capacity, surveillance systems, and distribution networks that can be activated quickly.
When the dust settles, the healthcare landscape will be different. The question is whether we will have learned enough from this experience to build something better, or whether we will simply revert to the pre-pandemic status quo and wait for the next crisis to remind us of what we should have done.
The dust is settling. What we do now will determine whether COVID-19 was a catalyst for genuine improvement or merely an expensive interruption.